2 results match your criteria: "People's Republic of China Southern Medical University[Affiliation]"
Int J Surg Pathol
August 2016
Nanfang Hospital, Tonghe, Guangzhou, People's Republic of China Southern Medical University, Tonghe, Guangzhou, People's Republic of China.
Oncologist
May 2016
Department of Oncology, Dongguan People's Hospital, Dongguan, People's Republic of China.
Background: The use of trastuzumab has proven to be a successful strategy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer; however, it is associated with an increased risk of cardiac dysfunction. We performed an up-to-date, comprehensive meta-analysis to clarify the risk of congestive heart failure (CHF) in patients with early breast cancer receiving different durations of adjuvant trastuzumab with the longest-term follow-up.
Methods: Eligible studies included randomized control trials of HER2-positive early breast cancer patients with or without trastuzumab in adjuvant chemotherapy.